Clinical trial
Inhalation of Liposomal Amphotericin B to Prevent Invasive Aspergillosis
NCT00263315 · Erasmus Medical Center, Other · Completed
Key facts
| NCT number | NCT00263315 |
|---|---|
| Title | Inhalation of Liposomal Amphotericin B to Prevent Invasive Aspergillosis |
| Official title | Nebulized Liposomal Amphotericin B (Ambisome) Versus Nebulized Placebo for the Prophylaxis of Invasive Pulmonary Aspergillosis in Haematological Patients With Prolonged Neutropenia. A Randomized Clinical Trial. |
| Lead sponsor | Erasmus Medical Center, Other |
| Collaborators | Gilead Sciences Industry Nexstar Pharmaceuticals |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Aspergillosis |
| Intervention type | Drug |
| Interventions | nebulised liposomal amphotericin B |
| Enrollment | 320 |
| Start date | Jan 1, 2000 |
| Completion | May 1, 2006 |
| First posted | Dec 8, 2005 |
| Last update posted | Aug 18, 2006 |
| Countries | Netherlands |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: